Ali Guner1,2, Taeil Son3,4, In Cho3,5, In Gyu Kwon3,6, Ji Yeong An1,7, Hyoung-Il Kim1,7,8, Jae-Ho Cheong1,7, Sung Hoon Noh1,7, Woo Jin Hyung9,10,11. 1. Department of Surgery, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea. 2. Department of General Surgery, Trabzon Kanuni Training and Research Hospital, Trabzon, Turkey. 3. Department of Surgery, Graduate School, Yonsei University College of Medicine, Seoul, South Korea. 4. Department of Surgery, Eulji Medical Center, Eulji University School of Medicine, Seoul, South Korea. 5. Department of Surgery, International St. Mary's Hospital, Incheon, South Korea. 6. Department of Surgery, Keimyung University School of Medicine, Daegu, South Korea. 7. Gastric Cancer Center, Yonsei Cancer Hospital, Yonsei University Health System, Seoul, South Korea. 8. Robot and MIS Center, Severance Hospital, Yonsei University Health System, Seoul, South Korea. 9. Department of Surgery, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea. wjhyung@yuhs.ac. 10. Gastric Cancer Center, Yonsei Cancer Hospital, Yonsei University Health System, Seoul, South Korea. wjhyung@yuhs.ac. 11. Robot and MIS Center, Severance Hospital, Yonsei University Health System, Seoul, South Korea. wjhyung@yuhs.ac.
Abstract
BACKGROUND: Although various liver-directed treatment modalities, such as liver resection and radiofrequency ablation (RFA), have been applied to treat liver metastases from gastric cancer, optimal management of them remains controversial. In patients with liver metastasis from gastric cancer, we investigated the short- and long-term outcomes of liver resection and RFA and analyzed factors influencing survival. METHODS: A total of 98 gastric cancer patients with liver metastasis and no extrahepatic disease were treated by liver resection (n = 68) or RFA (n = 30). Short- and long-term outcomes were evaluated retrospectively for each of the liver-directed treatments. RESULTS: Severe complication rates did not differ between liver resection (18 %) and RFA (10 %) (p = 0.333). Only one treatment-related mortality occurred in the liver resection group. No statistically significant difference in survival was noted between the treatment groups. Median overall survival after liver resection was 24 months, with 3-year overall and progression-free survival rates of 40.6 % and 30.4 %, respectively. Median overall survival after RFA was 23 months, with 3-year overall and progression-free survival rates of 43.0 % and 37.4 %, respectively. Only the size of the metastases was shown to be an independent prognostic factor for gastric cancer patients with liver metastasis. CONCLUSIONS: In select patients with liver metastasis from gastric cancer, liver resection and RFA showed satisfactory and comparable short- and long-term results. Thus, systemic chemotherapy may not be the only therapeutic option for patients with liver metastasis, and possible liver-directed treatment options for such patients should be considered on an individual basis.
BACKGROUND: Although various liver-directed treatment modalities, such as liver resection and radiofrequency ablation (RFA), have been applied to treat liver metastases from gastric cancer, optimal management of them remains controversial. In patients with liver metastasis from gastric cancer, we investigated the short- and long-term outcomes of liver resection and RFA and analyzed factors influencing survival. METHODS: A total of 98 gastric cancerpatients with liver metastasis and no extrahepatic disease were treated by liver resection (n = 68) or RFA (n = 30). Short- and long-term outcomes were evaluated retrospectively for each of the liver-directed treatments. RESULTS: Severe complication rates did not differ between liver resection (18 %) and RFA (10 %) (p = 0.333). Only one treatment-related mortality occurred in the liver resection group. No statistically significant difference in survival was noted between the treatment groups. Median overall survival after liver resection was 24 months, with 3-year overall and progression-free survival rates of 40.6 % and 30.4 %, respectively. Median overall survival after RFA was 23 months, with 3-year overall and progression-free survival rates of 43.0 % and 37.4 %, respectively. Only the size of the metastases was shown to be an independent prognostic factor for gastric cancerpatients with liver metastasis. CONCLUSIONS: In select patients with liver metastasis from gastric cancer, liver resection and RFA showed satisfactory and comparable short- and long-term results. Thus, systemic chemotherapy may not be the only therapeutic option for patients with liver metastasis, and possible liver-directed treatment options for such patients should be considered on an individual basis.
Authors: Srinevas K Reddy; Andrew S Barbas; Carlos E Marroquin; Michael A Morse; Paul C Kuo; Bryan M Clary Journal: J Am Coll Surg Date: 2007-03 Impact factor: 6.113
Authors: Ji Fu Lai; Sungsoo Kim; Kiyeol Kim; Chen Li; Sung Jin Oh; Woo Jin Hyung; Sun Young Rha; Hyun Cheol Chung; Seung Ho Choi; Lin Bo Wang; Sung Hoon Noh Journal: Ann Surg Oncol Date: 2009-05-12 Impact factor: 5.344
Authors: Francesco De Cobelli; Paolo Marra; Francesca Ratti; Alessandro Ambrosi; Michele Colombo; Anna Damascelli; Claudio Sallemi; Simone Gusmini; Marco Salvioni; Pietro Diana; Federica Cipriani; Massimo Venturini; Luca Aldrighetti; Alessandro Del Maschio Journal: Med Oncol Date: 2017-02-20 Impact factor: 3.064
Authors: Yoshikuni Kawaguchi; Mario De Bellis; Elena Panettieri; Gregor Duwe; Jean-Nicolas Vauthey Journal: Surg Oncol Clin N Am Date: 2020-10-27 Impact factor: 3.495